Lise Soldbro
Zealand Pharma (Denmark)(DK)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Food Allergy and Anaphylaxis Research, Clinical Nutrition and Gastroenterology, Diet and metabolism studies
Most-Cited Works
- → Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis(2023)125 cited
- → Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)*(2021)89 cited
- → Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial(2022)11 cited
- → Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome(2025)3 cited
- → The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial(2023)1 cited
- → Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial(2021)
- → Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial(2022)
- → 324 Tralokinumab provides progressive and sustained efficacy in adolescents with moderate-to-severe atopic dermatitis: a post-hoc analysis of the ECZTRA 6 trial(2023)
- → The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial(2022)
- → Changes in intestinal absorption following 24-weeks of treatment with glepaglutide in patients with short bowel syndrome(2024)